Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rigel Pharmaceuticals Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.rigel.com
Year Founded: 1996
Status: Public
Industry Sector: HealthTechnology
CEO: Raul R. Rodriguez, MBA
Number Of Employees: 164
Enterprise Value: $280,139,340
PE Ratio: 17.74
Exchange/Ticker 1: NASDAQ:RIGL
Exchange/Ticker 2: N/A
Latest Market Cap: $307,958,112
BioCentury | Apr 1, 2025
Distillery Therapeutics
Inhibiting interactions between FAM171A2 and alpha-synuclein for Parkinson’s disease
BioCentury | Mar 13, 2024
Management Tracks
IDRx names Clackson, Dahms to C-suite and Auspitz chair
Plus: new COO for radiopharma
BioCentury | Feb 27, 2024
Deals
Deals report: Novo-Neomorph seek degraders, Column Group taking NGM private, and more
Plus: agreements between Rigel-Blueprint, BeiGene-Shoreline and AstraZeneca-FibroGen
BioCentury | Dec 7, 2023
Emerging Company Profile
GenFleet: building a fleet of first-in-class cancer and immune therapies
With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapies
BioCentury | Oct 5, 2023
Management Tracks
Jonsson to succeed Mason as head of Lilly Diabetes and Obesity
Plus: Grabulovski takes over as CEO of Araris and updates from IGM, Odyssey, Alpine, Nuvig, Rome, Saghmos, Nature’s Toolbox and Myricx
BioCentury | Jan 26, 2023
Management Tracks
Juvena hires three new senior executives
Plus: new CEO at ClostraBio, and updates from Cambrian and Pliant
BioCentury | Dec 2, 2022
Regulation
Dec. 1 Quick Takes: FDA approves Rigel, Forma therapy for AML
Plus: Pfizer, Roivant form new unit around ulcerative colitis target, China’s Trinomab raises over $100M and updates from Nordic-APIM, Nectin, NIST and more
BioCentury | Sep 1, 2022
Deals
$1.1B Forma buyout gives Novo advanced sickle cell asset with potential for accelerated approval
Latest takeout in SCD is the culmination of Forma’s realignment around its internal pipeline
BioCentury | Aug 3, 2022
Finance
Aug. 2 Quick Takes: Yescarta label expansion buoys Gilead’s 2Q22 sales
Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more
BioCentury | Jun 9, 2022
Finance
June 8 Quick Takes: Fundings for Ariceum, Synklino, Anagenex and Biospring
Plus CureVac hiring Novartis’ Mendila, adding antigen discovery platform via Frame takeout, and updates from Aldeyra, Astellas, PineTree and more
Items per page:
1 - 10 of 319